Cipla Acquires Full Stake in Inzpera Healthsciences
Filing Summary
Cipla Ltd has completed the acquisition of a 100% stake in Inzpera Healthsciences Limited as of December 4, 2025. This transaction results in Inzpera becoming a wholly owned subsidiary of Cipla. The acquisition aligns with Cipla’s strategic objectives under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously notified stakeholders of this intent on November 3, 2025. This update was communicated to the BSE, NSE, and the Societe de la Bourse de Luxembourg.
Cipla Ltd has announced the completion of its acquisition of a 100% stake in Inzpera Healthsciences Limited as of December 4, 2025. This acquisition results in Inzpera becoming a wholly owned subsidiary of Cipla. The transaction was conducted in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company had previously informed stakeholders of its intent to acquire Inzpera on November 3, 2025. The update regarding the completion of this acquisition was communicated to the BSE Ltd, the National Stock Exchange of India Ltd, and the Societe de la Bourse de Luxembourg.
Cipla Ltd is a global pharmaceutical company focused on the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company prioritizes expanding its portfolio through strategic acquisitions and partnerships to enhance its market presence and product offerings.